Evaluation of Aminocamptothecin (9-AC, NSC #603071 [IDEC 132]) in Recurrent, Platinum Resistant and Refractory Ovarian Cancer and Primary Peritoneal Carcinoma
Phase of Trial: Phase II
Latest Information Update: 20 Jun 2013
At a glance
- Drugs IDEC 132 (Primary)
- Indications Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 01 Nov 2007 Status changed from in progress to completed.
- 17 Sep 2005 New trial record.